Lilly Acquires Merida to Advance Treatments for Autoimmune and Allergic Diseases

Eli Lilly will acquire Merida Biosciences for up to $2.875 billion. Merida aims to remove disease-causing antibodies in Graves’ disease, TED and allergies.